Mr. Adam Xu China

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.
Website:
www.trustwe.com
Company Size (Fulltime employees)
Year of foundation
2007
Partnering Objectives
Please specify your partnering goal
Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals.
Headquartner in China
Shanghai T&W Pharmaceutical Co., Ltd.
BD Director 
Functionality

wenlian xu China

New drug development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
GH Therapeutics
CEO 

Zheng Xu China

Leading Investment and security company in China
Partnering Objectives
Headquartner in China
Guotaijunan security
Director 

shuyang xu China

天士力
Website:
www.tasly.com
Partnering Objectives
Headquartner in China
tasly
bd manager 

John Xu United States

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800

Website:
www.Abpro.com
Partnering Objectives
Headquartner in China
Abpro
SVP 

Shawn Xu

Simcere Innovation
Managing Director and COO 

Siyuan Xu China

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.
Partnering Objectives
Headquartner in China
VISEN Pharmaceutical
Senior BD Manager 

Mr. Evan Xu China

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Company Size (Fulltime employees)
Year of foundation
2015
Please specify your partnering goal
N/A
Headquartner in China
Genetron Health
Chief Financial Officer 
Functionality

Yuan Xudong United States

Please contact us using Acon Pharmaceutical Inc. 

Headquartner in China
Pharma - Acon Pharma
CEO 
Functionality

Mr. Ning Yan United States

Specialized in oncology
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Knowing the trend
Headquartner in China
Taiho
Director